107 related articles for article (PubMed ID: 12199631)
21. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies.
Minami H; Lad TE; Nicholas MK; Vokes EE; Ratain MJ
Clin Cancer Res; 1999 Jun; 5(6):1325-30. PubMed ID: 10389915
[TBL] [Abstract][Full Text] [Related]
23. A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report.
Chang SM; Kuhn JG; Robins HI; Schold SC; Spence AM; Berger MS; Mehta M; Pollack IF; Rankin C; Prados MD
Cancer; 2001 Jan; 91(2):417-22. PubMed ID: 11180089
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
Buckner JC; Reid JM; Wright K; Kaufmann SH; Erlichman C; Ames M; Cha S; O'Fallon JR; Schaaf LJ; Miller LL
Cancer; 2003 May; 97(9 Suppl):2352-8. PubMed ID: 12712456
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Schoemaker NE; Kuppens IE; Huinink WW; Lefebvre P; Beijnen JH; Assadourian S; Sanderink GJ; Schellens JH
Cancer Chemother Pharmacol; 2005 Mar; 55(3):263-70. PubMed ID: 15592838
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Chen TC; Su S; Fry D; Liebes L
Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
[TBL] [Abstract][Full Text] [Related]
29. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Clarke JL; Molinaro AM; Cabrera JR; DeSilva AA; Rabbitt JE; Prey J; Drummond DC; Kim J; Noble C; Fitzgerald JB; Chang SM; Butowski NA; Taylor JW; Park JW; Prados MD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):603-610. PubMed ID: 28233053
[TBL] [Abstract][Full Text] [Related]
30. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
[TBL] [Abstract][Full Text] [Related]
31. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.
Takahashi T; Fujiwara Y; Sumiyoshi H; Isobe T; Yamaoka N; Yamakido M
Cancer Chemother Pharmacol; 1997; 40(5):449-52. PubMed ID: 9272124
[TBL] [Abstract][Full Text] [Related]
32. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Chester JD; Joel SP; Cheeseman SL; Hall GD; Braun MS; Perry J; Davis T; Button CJ; Seymour MT
J Clin Oncol; 2003 Mar; 21(6):1125-32. PubMed ID: 12637480
[TBL] [Abstract][Full Text] [Related]
34. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
Bomgaars L; Kerr J; Berg S; Kuttesch J; Klenke R; Blaney SM
Pediatr Blood Cancer; 2006 Jan; 46(1):50-5. PubMed ID: 15768380
[TBL] [Abstract][Full Text] [Related]
36. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.
Batchelor TT; Gilbert MR; Supko JG; Carson KA; Nabors LB; Grossman SA; Lesser GJ; Mikkelsen T; Phuphanich S;
Neuro Oncol; 2004 Jan; 6(1):21-7. PubMed ID: 14769136
[TBL] [Abstract][Full Text] [Related]
39. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
van Riel JM; van Groeningen CJ; Kedde MA; Gall H; Leisink JM; Gruia G; Pinedo HM; van der Vijgh WJ; Giaccone G
Clin Cancer Res; 2002 Feb; 8(2):405-12. PubMed ID: 11839656
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.
Vassal G; Doz F; Frappaz D; Imadalou K; Sicard E; Santos A; O'Quigley J; Germa C; Risse ML; Mignard D; Pein F
J Clin Oncol; 2003 Oct; 21(20):3844-52. PubMed ID: 14551303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]